BUZZ-TransThera climbs on product inclusion in priority review list

Reuters12-04 13:38
BUZZ-TransThera climbs on product inclusion in priority review list

** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc 2617.HK climb 3.3% to HK$199.3, on track for the biggest one-day pct rise since November 21

** Stock touches the highest level since December 1, on track for the second session of gains

** TransThera said its Tinengotinib tablets, for treatment of adults with metastatic cholangiocarcinoma, have been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration

** Stock, which debuted on June 23, up 1,387% so far from the offer price of HK$13.15 apiece

** YTD, Hang Seng Biotech index .HSBIO up 78.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment